SecBot SecBot
SECBOTREPLAY Home › Report › CHRS

CHRS · Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of…

Coherus Oncology, Inc. · PRESS-RELEASE filed May 11, 2026 at 16:05 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 11, 2026 at 16:05 ET

Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14.3M estimate by 14.0%. LOQTORZI revenue grew 61% YoY to $11.8M, but total revenue was dragged lower than expected, and the company completed a dilutive $53.6M equity offering during the quarter.

  • GAAP EPS from continuing operations: -$0.27 vs consensus -$0.29 (beat by 6.9%)
  • Revenue: $12.3M vs consensus $14.3M (miss by 14.0%)
  • LOQTORZI net product revenue: $11.8M, up 61% YoY from $7.3M
  • Net loss from continuing operations improved to -$36.9M from -$47.4M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access